Skip to main content

Advertisement

SpringerLink
Log in

Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals

  • Published:
Inflammation Aims and scope Submit manuscript

Abstract

Background: The Framingham Risk Score (FRS) is widely recommended to estimate global risk for cardiovascular (CV) disease; however, it does not recognize all individuals with a high risk for coronary artery disease, because it does not take into account the various novel markers, such as the C-reactive protein levels (CRP). The present study aims to describe the profile of the simvastatin users and non-users in relation to FRS and high-sensitivity CRP (hs-CRP) levels. Methods: In this cross-sectional study, 277 European descent individuals were divided in two groups: 177 using simvastatin 20 mg per day (T+) and 100 not using simvastatin (T−). TC, HDL-C, TG, glucose and hs-CRP levels were determined by standard methods and the FRS was calculated. Results: The individuals in T+ sample were more prevalent in high risk group (according FRS score) than individuals in T− sample (p < 0.0001; adjusted residual = 4.21). All the individuals, users and non-users, were simultaneously classified by FRS and hs-CRP levels and no significant differences were found, even though 21.6% of those individuals in T− showed high hs-CRP levels they were in the low CV risk group, as well as 9.9% of the simvastatin users. Conclusions: Considering that some works have shown CRP as an independent risk factor of CV and that statins could reduce CRP levels and prevent CV events, our findings show that some people that might benefit from the pleiotropic effect of statin remain without treatment if the decision is based only in those classical risk factors present in FRS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. 2002. Circulation 106: 3143–3421.

  2. DATASUS Ministério da Saúde- Indicadores de mortalidade <http://tabnet.datasus.gov.br> Access in 02/10/2007.

  3. Wilson, P.W., R.B. D’Agostino, D. Levy, A.M. Belanger, H. Silbershatz, and W.B. Kannel. 1998. Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837–1847.

    CAS  PubMed  Google Scholar 

  4. Grewal, J., S. Chan, J. Frohlich, and G.B. Mancini. 2003. Assessment of novel risk factors in patients at low risk for cardiovascular events based on Framingham risk stratification. Clinical and Investigative Medicine 26: 158–165.

    PubMed  Google Scholar 

  5. Ross, R. 1999. Atherosclerosis: an inflammatory disease. New England Journal of Medicine 340: 115–126.

    Article  CAS  PubMed  Google Scholar 

  6. Ridker, P.M., N. Rifai, L. Rose, J.E. Buring, and N.R. Cook. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine 347: 1557–1565.

    Article  CAS  PubMed  Google Scholar 

  7. Albert, M.A., R.J. Glynn, and P.M. Ridker. 2003. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108: 161–165.

    Article  CAS  PubMed  Google Scholar 

  8. Koenig, W., H. Löwel, J. Baumert, and C. Meisinge. 2004. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109: 1349–1353.

    Article  PubMed  Google Scholar 

  9. Pai, J.K., T. Pischon, J. Ma, J.E. Manson, S.E. Hankinson, K. Joshipura, G.C. Curhan, N. Rifai, C.C. Cannuscio, M.J. Stampfer, and E.B. Rimm. 2004. Inflammatory markers and the risk of coronary heart disease in men and women. New England Journal of Medicine 351: 2599–2610.

    Article  CAS  PubMed  Google Scholar 

  10. Pearson, T.A., G.A. Mensah, R.W. Alexander, J.L. Anderson, R.O. Cannon3rd, M. Criqui, Y.Y. Fadl, S.P. Fortmann, Y. Hong, G.L. Myers, N. Rifai, S.C. Smith SC, K. Taubert, R.P. Tracy, F. Vinicor, and Centers for Disease Control and Prevention, American Heart Association. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511.

    Article  PubMed  Google Scholar 

  11. Jialal, I., S. Verma, and S. Devaraj. 2009. Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clinical Chemistry 55: 206–208.

    Article  CAS  PubMed  Google Scholar 

  12. Zacho, J., A. Tybjaerg-Hansen, J.S. Jensen, P. Grande, H. Sillesen, and B.G. Nordestgaard. 2008. Genetically elevated C-reactive protein and ischemic vascular disease. New England Journal of Medicine 359: 1897–1908.

    Article  CAS  PubMed  Google Scholar 

  13. Schmitz, G., and T. Langmann. 2006. Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharmacology 44: 75–89.

    Article  CAS  PubMed  Google Scholar 

  14. Takemoto, M., and J.K. Liao. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology 21: 1712–1719.

    Article  CAS  PubMed  Google Scholar 

  15. Palinski, W. 2001. New evidence for beneficial effects of statins unrelated to lipid lowering. Arteriosclerosis, Thrombosis, and Vascular Biology 21: 3–5.

    CAS  PubMed  Google Scholar 

  16. Laufs, U., V. La Fata, J. Plutzky, and J.K. Liao JK. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129–1135.

    CAS  PubMed  Google Scholar 

  17. Hernandez-Perera, O., D. Perez-Sala, J. Navarro-Antolin, R. Sanchez-Pascuala, G. Hernandez, C. Diaz, and S. Lamas. 1998. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. The Journal of Clinical Investigation 101: 2711–2719.

    Article  CAS  PubMed  Google Scholar 

  18. Wassmann, S., U. Laufs, K. Müller, C. Konkol, K. Ahlbory, A.T. Bäumer, W. Linz, M. Böhm, and G. Nickenig. 2002. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 22: 300–305.

    Article  CAS  PubMed  Google Scholar 

  19. Shishehbor, M.H., M.L. Brennan, R.J. Aviles, X. Fu, M.S. Penn, D.L. Sprecher, and S.L. Hazen. 2003. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108: 426–431.

    Article  CAS  PubMed  Google Scholar 

  20. Cordle, A., J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth. 2005. Mechanism of statin-mediated inhibition of Small G-protein function. The Journal of Biological Chemistry 280: 34202–34209.

    Article  CAS  PubMed  Google Scholar 

  21. Davignon, J. 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109: III39–III43.

    PubMed  Google Scholar 

  22. Friedwald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502.

    Google Scholar 

  23. Katrinchak, C., and K. Fritz. 2007. Clinical implications of C-reactive protein as a predictor of vascular risk. Journal of the American Academy of Nurse Practitioners 19: 335–340.

    Article  PubMed  Google Scholar 

  24. Downs, J.R., M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, and A.M. GottoJr. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279: 1615–1622.

    Article  CAS  PubMed  Google Scholar 

  25. Shepherd, J., S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. MacKillop, and C.J. Packhard. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine 333: 1301–1307.

    Article  CAS  PubMed  Google Scholar 

  26. Simes, R.J., I.C. Marschner, D. Hunt, D. Colquhoun, D. Sullivan, R.A. Stewart, W. Hague, A. Keech, P. Thompson, H. White, J. Shaw, A. Tonkin, and LIPID Study Investigators. 2002. A Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial: To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105: 1162–1169.

    Article  CAS  PubMed  Google Scholar 

  27. Schwartz, G.G., A.G. Olsson, M.D. Ezekowitz, P. Ganz, M.F. Oliver, D. Waters, A. Zeiher, B.R. Chaitman, S. Leslie, T. Stem, and Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. 2001. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718.

    Article  CAS  PubMed  Google Scholar 

  28. Ridker, P.M. 2009. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clinical Chemistry 55: 209–215.

    Article  CAS  PubMed  Google Scholar 

  29. Sattar, N., H.M. Murray, P. Welsh, G.J. Blauw, B.M. Buckley, S. Cobbe, A.J. de Craen, G.D. Lowe, J.W. Jukema, P.W. Macfarlane, M.B. Murphy, D.J. Stott, R.G. Westendorp, J. Shepherd, I. Ford, C.J. Packard, and Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. 2009. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med 6: e1000099.

    Article  PubMed  Google Scholar 

  30. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). 2007. European Journal of Cardiovascular Prevention and Rehabilitation 14(Suppl 2): E1–E40.

  31. Ridker, P.M., J.E. Buring, N. Rifai, and N.R. Cook. 2007. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297: 611–619.

    Article  CAS  PubMed  Google Scholar 

  32. Ridker, P.M., N.P. Paynter, N. Rifai, J.M. Gaziano, and N.R. Cook. 2008. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118: 2243–2251.

    Article  CAS  PubMed  Google Scholar 

  33. Nissen, S.E., E.M. Tuzcu, P. Schoenhagen, T. Crowe, W.J. Sasiela, J. Tsai, J. Orazem, R.D. Magorien, C. O’Shaughnessy, P. Ganz, and Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. 2005. Statin therapy, LDL cholesterol, C-reactive protein, and Coronary artery Disease. New England Journal of Medicine 352: 29–38.

    Article  CAS  PubMed  Google Scholar 

  34. Ridker, P.M., C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, E. Braunwald, and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. 2005. C-reactive protein levels and outcomes after statin therapy. New England Journal of Medicine 352: 20–28.

    Article  CAS  PubMed  Google Scholar 

  35. Stewart, R.A. 2009. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. Future Cardiol 5: 231–236.

    Article  PubMed  Google Scholar 

  36. Ridker, P.M., E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto, J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn, and JUPITER Study Group. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 359: 2195–2207.

    Article  CAS  PubMed  Google Scholar 

  37. Glynn, R.J., J.G. MacFadyen, and P.M. Ridker. 2009. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clinical Chemistry 55: 305–312.

    Article  CAS  PubMed  Google Scholar 

  38. Weitz-Schmidt, G. 2002. Statins as anti-inflammatory agents. Trends in Pharmacological Sciences 23: 482–486.

    Article  CAS  PubMed  Google Scholar 

  39. Kinlay, S. 2007. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. Journal of the American College of Cardiology 49: 2003–2009.

    Article  CAS  PubMed  Google Scholar 

  40. Ansell, B.J., K.E. Watson, R.E. Weiss, and G.C. Fonarow. 2003. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation. Heart Disease 5: 2–7.

    Article  CAS  PubMed  Google Scholar 

  41. Arnaud, C., V. Braunersreuther, and F. Mach. 2005. Toward immunomodulatory and anti-inflammatory properties of statins. Trends in Cardiovascular Medicine 15: 202–206.

    Article  CAS  PubMed  Google Scholar 

  42. Koh, K.K., M.J. Quon, S.H. Han, J.Y. Ahn, D.K. Jin, H.S. Kim, D.S. Kim, and E.K. Shin. 2005. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45: 1088–1093.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Financial support was provided by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil). Thanks to Mr. José Carlos Mamprim, Santa Catarina Laboratory, for his assistance in managing blood samples and hs-CRP and lipid levels dosage.

Author information

Authors and Affiliations

  1. Laboratório de Fisiopatologia Experimental, Universidade do Extremo Sul Catarinense, Criciúma, Santa Catarina, Brazil

    Alexandre B. Rosendo & Felipe Dal-Pizzol

  2. Laboratório de Biologia Molecular, Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil

    Luciana O. Lima & Silvana Almeida

  3. Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite, 245-sala 309, Porto Alegre, 90050-170, Rio Grande do Sul, Brazil

    Silvana Almeida

Authors
  1. Alexandre B. Rosendo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luciana O. Lima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felipe Dal-Pizzol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvana Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvana Almeida.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosendo, A.B., Lima, L.O., Dal-Pizzol, F. et al. Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals. Inflammation 33, 244–250 (2010). https://doi.org/10.1007/s10753-009-9178-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10753-009-9178-3

KEY WORDS

Search

Navigation